Abstract
The over-expression/amplification of the epidermal growth factor receptor (EGFR) gene and mutation/deletion of tumor suppressor PTEN gene are main genetic changes identified in glioblastomas. These two genetic changes play a critical role in the formation of many malignant tumors and have been shown to be the important therapeutic targets. In this study, we used an expression plasmid that expresses small hairpin RNA-targeting sequences of human EGFR and wild-type PTEN cDNA to examine the growth inhibitive effects in U251 glioma cells. It was found that down-regulation of EGFR expression and up-regulation of PTEN expression resulted in the suppression of cell proliferation, arrest of cell cycle, reduction in cell invasion and promotion of cell apoptosis in vitro. In addition, the growth of the subcutaneous U251 glioma in the nude mice treated with expression plasmid was significantly inhibited. Our results demonstrated that the expression plasmid could exert proliferation and invasion inhibition effects on U251 cells in vitro and in vivo. It suggested that combinatory gene therapy targeting EGFR and PTEN would be a new strategy in gene therapy of glioblastoma.
Similar content being viewed by others
References
James CD, Olson JJ. Molecular genetics and molecular biology advances in brain tumors. Curr Opin Oncol. 1996;8:188–95.
Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet. 1995;11:412–5.
Westermark B, Nister M. Molecular genetics of human glioma. Curr Opin Oncol. 1995;7:220–5.
Ng HK, Lam PYP. The molecular genetics of central nervous system tumors. Pathology. 1998;30:196–202.
Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313:144–7.
Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.
Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.
Wells A. EGF receptor: review. Int J Biochem Cell. 1999;31:637–43.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–665.
Liu XW, Pu PY, Gao ZX, et al. Study on the expression of epidermal growth factor receptor gene in human gliomas. Chin J Neurosurg. 1998;14:71–4.
Pu P, Liu X, Liu A, et al. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. J Neurosurg. 2000;92:132–9.
Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–90.
Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406–11.
Kang CS, Zhang ZY, Jia ZF, et al. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 2006;13:1–9.
Pu PY, Kang CS, Zhang ZY, et al. Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat. 2006;5:271–80.
Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mousealternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71:1–20.
Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311–33.
Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas. Int J Oncol. 2004;24:1101–9.
Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 2003;13:473–83.
Haas-Kogan D, Shalev N, Wong M, et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998;8:1195–8.
Leslie NR, Downes CP. PTEN: the down side of PI3-kinase signaling. Ce Signal. 2002;14:285–95.
Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 2001;98:10983–5.
Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3 K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res. 2007;32:2194–202.
Liu W, James CD, Frederick L, et al. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997;57:5254–7.
Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol. 1998;143:1375–83.
Tian XX, Zhang YG, Du J, et al. Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells. Neuropathology. 2006;26:178–87.
Yang YC, Huang WF, Chuan LM, et al. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy. 2008;54:438–46.
Oliveira MG, Lauxen IS, Chaves AC, et al. Immunohistochemical analysis of the patterns of p53 and PCNA expression in odontogenic cysticlesions. Med Oral Pathol Oral Cir Bucal. 2008;13:E275–80.
Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ducta1 carcinoma in situ of the breast. Breast Cancer Res Treat. 2003;79:187–98.
Yamamoto H, Ochiya T, Takeshita F, et al. Enhanced skin carcinogenesis in cyclin D1—conditional transgenic mice: cyclin Dl alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res. 2002;62:1641–7.
Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6.
Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995;267:1506–10.
Nakayama K, Nakayama K, Negishi I, et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science. 1993;261:1584–8.
Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426:671–6.
Veis DJ, Sorenson CM, Shutter JR, et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993;75:229–40.
Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558–64.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73.
Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 2006;20:983–1002.
Acknowledgments
This work was supported by Program for New Century Excellent Talents in University (NCET-07-0615) and Key Project Foundation from Tianjin Science and Technology Committee (No. 09JCZDJC17600) to which the authors wish to express their thanks.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, L., Zhang, Al., Xu, P. et al. Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo. Med Oncol 27, 843–852 (2010). https://doi.org/10.1007/s12032-009-9295-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-009-9295-8